Pfizer YaoPharma Deal Brings YP05002 In-House
Pfizer YaoPharma deal gives Pfizer exclusive rights to oral GLP-1 candidate, expanding its obesity pipeline and putting traders on clinical milestones.
KEY TAKEAWAYS
- Pfizer gained an exclusive license to YP05002 with $150 million upfront and up to $1.9 billion in milestones.
- Deal allows Pfizer to run combination trials with its GIPR antagonist.
- YaoPharma will complete the Phase 1 trial in Australia before Pfizer assumes global development.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Pfizer Inc. (PFE) announced on Dec. 9, 2025, an exclusive global license agreement with YaoPharma for YP05002, a Phase 1 oral small-molecule GLP-1 receptor agonist targeting obesity. The deal expands Pfizer’s obesity pipeline and enables planned combination trials with internal assets.
Deal Terms and Strategic Context
Pfizer will pay $150 million upfront and up to $1.935 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on net sales, valuing the deal at about $2.085 billion, the company said in a press release. The exclusive license covers development, manufacturing, and commercialization of YP05002 and any oral small-molecule GLP-1 receptor agonists as active ingredients. Milestone payments depend on achieving development, regulatory, and commercial goals.
Pfizer plans combination studies with PF-07976016, a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist in Phase 2, and other small molecules in its pipeline. The release included standard forward-looking language about clinical and regulatory risks. Chris Boshoff, M.D., Ph.D., Pfizer’s chief scientific officer and president of research and development, said, “Cardiometabolic research is a strategic priority for Pfizer that has the potential to be a key driver of growth for our business.”
YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited, independently developed YP05002 and will complete the ongoing Phase 1 trial in Australia, Fosun said in a separate release. The candidate is positioned for chronic weight management and related metabolic conditions, including type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH/NASH).
Candidate Profile and Development Plan
YP05002 is an oral small-molecule GLP-1 receptor agonist aimed at chronic weight management, a market currently dominated by injectable GLP-1 therapies from Novo Nordisk and Eli Lilly. Oral formulations must demonstrate clear advantages in tolerability, efficacy, or cost to gain market share. Pfizer’s earlier oral candidates, including danuglipron, failed due to safety issues.
An analyst from Leerink Partners noted that YP05002’s chemical scaffold resembles Lilly’s orforglipron and differs from Pfizer’s danuglipron. The deal follows Pfizer’s $10 billion acquisition of Metsera, reflecting the company’s broader push into obesity treatments.
YaoPharma will complete the ongoing Phase 1 trial in Australia, after which Pfizer will assume global development and commercialization. Planned combination studies with Pfizer’s PF-07976016 and other pipeline molecules aim to explore synergistic effects. The commercial success of the deal depends on clinical outcomes and milestone achievements.
